Literature DB >> 4270346

Effect of immunosuppression on chronic LCM virus infection of mice.

P E Hoffsten, F J Dixon.   

Abstract

C3H mice chronically infected with LCM virus were found to be lethally affected by small doses of immunosuppression which caused bone marrow aplasia but had no effect on the amount of virus carried by the mouse. Humoral immune response of SWR/J mice to acute LCM infection was found to be totally suppressed by repeated single doses of 300 R/wk with no alteration in the level of virus carried by the mouse. In contrast, the established anti-LCM humoral immune response encountered in mice chronically infected with LCM virus was not suppressed by the same irradiation procedure. Over half of the chronic LCM carrier SWR/J mice treated with cyclophosphamide for 6 mo had total anti-LCM humoral immunosuppression, but showed no change in the level of virus carried. The glomerulonephritis which occurs in chronic LCM carrier mice was prevented by cyclophosphamide treatment in 90% of the mice. The humoral immune response which occurs in chronic LCM carrier mice appears to play no role in controlling the amount of virus carried by the mouse. Suppression of the LCM immune response by cyclophosphamide does prevent the development of glomerulonephritis in these mice.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4270346      PMCID: PMC2180570          DOI: 10.1084/jem.138.4.887

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  Haemopoietic defects in mice infected with lymphocytic choriomeningitis virus. 2. The viral effect upon the function of colony-forming stem cells.

Authors:  K Bro-Jorgensen; M Volkert
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1972

2.  Presidential address. Pathogenesis of immunologic disease.

Authors:  F J Dixon
Journal:  J Immunol       Date:  1972-08       Impact factor: 5.422

Review 3.  Bright's disease today: the pathogenesis and treatment of glomerulonephritis. II.

Authors:  J S Cameron
Journal:  Br Med J       Date:  1972-10-21

4.  Immunosuppressive treatment of proliferative glomerulonephritis.

Authors:  M B Strauss
Journal:  N Engl J Med       Date:  1971-09-09       Impact factor: 91.245

5.  Hypocomplementemic (membranoproliferative) glomerulonephritis. Immunosuppressive therapy.

Authors:  N H Holland; N M Bennett
Journal:  Am J Dis Child       Date:  1972-05

6.  Experience of immunosuppressive therapy of glomerular disease in adults.

Authors:  J Ahlmén; P O Attman; Y U Bengtsson
Journal:  Acta Med Scand       Date:  1971-11

7.  Immunosuppressive therapy of proliferative glomerulonephritis in children.

Authors:  R E Urizar; B Tinglof; R McIntosh; N Litman; E Barnett; J Wilkerson; F Smith; R L Vernier
Journal:  Am J Dis Child       Date:  1969-09

8.  Immunosuppressive therapy in adults with proliferative glomerulonephritis. Controlled trial.

Authors:  L J Booth; G M Aber
Journal:  Lancet       Date:  1970-11-14       Impact factor: 79.321

9.  Augmented incidence of neoplasia in female New Zealand black-New Zealand white (NZB-NZW) mice treated with long-term cyclophosphamide.

Authors:  S E Walker; G G Bole
Journal:  J Lab Clin Med       Date:  1971-12

10.  Infectious virus-antibody complex in the blood of chronically infected mice.

Authors:  A L Notkins; S Mahar; C Scheele; J Goffman
Journal:  J Exp Med       Date:  1966-07-01       Impact factor: 14.307

View more
  4 in total

1.  Increased survival times of New Zealand hybrid mice immunosuppressed by graft-versus-host reactions.

Authors:  D H Lehman; C B Wilson; F J Dixon
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

Review 2.  Viral infections, their influence on some parts of the immune system and glomerulonephritis development.

Authors:  A Steciwko
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

3.  Response of sublethally irradiated monkeys to a replicating viral antigen.

Authors:  D E Hilmas; R O Spertzel
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

4.  Persistent viral infection elevates central nervous system MHC class I through chronic production of interferons.

Authors:  Phi Truong; Sara Heydari; Lucile Garidou; Dorian B McGavern
Journal:  J Immunol       Date:  2009-08-28       Impact factor: 5.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.